U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07239011) titled 'Dapagliflozin in Depression' on Nov. 15.
Brief Summary: Major depressive disorder (MDD) is currently one of the leading causes of disability and suicidal death worldwide, and despite extensive research and massive improvements in mental health, the nature of MDD remains ambiguous. Moreover, about two-thirds of MDD patients fail to optimally respond to currently available standard therapies, and many of them suffer from treatment-resistant depression
Study Start Date: Nov. 20
Study Type: INTERVENTIONAL
Condition:
Depression
Intervention:
DRUG: Fluoxetine
Fluoxetine is an antidepressant medication of the selective serotonin reu...